Treatment with sublingual minoxidil was safe and associated with increased scalp hair growth in men and women with pattern hair loss, according to findings from a phase 1b clinical trial published in the Journal of the European Academy of Dermatology and Venereology.

According to the study researchers, sublingual minoxidil is expected to reduce the risk for hemodynamic side effects and improve safety compared with oral dosing. To evaluate the sublingual vs oral minoxidil formulation, the investigators randomly assigned 40 men and women (age range, 30-65 years) to either 0.45 mg sublingual minoxidil (n=20) or placebo (n=20) daily for 24 weeks.

Read the full article at